Literature DB >> 20447524

Biomarkers of peripheral arterial disease.

John P Cooke1, Andrew M Wilson.   

Abstract

Atherosclerotic arterial occlusive disease affecting the lower extremities is also known as peripheral artery disease (PAD). This disorder affects 8 to 12 million individuals in the U.S. and is increasingly prevalent in Europe and Asia. Unfortunately, most patients are not diagnosed and are not optimally treated. A blood test for PAD, if sufficiently sensitive and specific, would be expected to improve recognition and treatment of these individuals. Even a biomarker panel of moderate sensitivity and specificity for PAD could refine risk stratification to select individuals for diagnostic vascular examination. Alternatively, biomarkers for PAD may be useful in determining prognosis, the risk for progression, or the response to therapy. Finally, the discovery of biomarkers associated with PAD may provide novel insights into the pathophysiology of PAD and new therapeutic avenues to pursue. Biomarkers may be derived from studies of the genome, transcriptome, proteome, or metabolome. The focus of this review is on proteomic biomarkers associated with PAD. Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447524      PMCID: PMC3157958          DOI: 10.1016/j.jacc.2009.08.090

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  87 in total

1.  Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study.

Authors:  Sotirios Tsimikas; Stefan Kiechl; Johann Willeit; Manuel Mayr; Elizabeth R Miller; Florian Kronenberg; Qingbo Xu; Claes Bergmark; Siegfried Weger; Friedrich Oberhollenzer; Joseph L Witztum
Journal:  J Am Coll Cardiol       Date:  2006-05-15       Impact factor: 24.094

Review 2.  Cellular adhesion molecules and peripheral arterial disease.

Authors:  Gregorio Brevetti; Vittorio Schiano; Massimo Chiariello
Journal:  Vasc Med       Date:  2006-02       Impact factor: 3.239

3.  Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease.

Authors:  Friedrich Mittermayer; Katarzyna Krzyzanowska; Markus Exner; Wolfgang Mlekusch; Jasmin Amighi; Schila Sabeti; Erich Minar; Markus Müller; Michael Wolzt; Martin Schillinger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-08-24       Impact factor: 8.311

4.  The United States preventive services task force recommendation statement on screening for peripheral arterial disease: more harm than benefit?

Authors:  Joshua A Beckman; Michael R Jaff; Mark A Creager
Journal:  Circulation       Date:  2006-08-22       Impact factor: 29.690

5.  The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Matthew A Allison; Michael H Criqui; Robyn L McClelland; JoAnn M Scott; Mary M McDermott; Kiang Liu; Aaron R Folsom; Alain G Bertoni; A Richey Sharrett; Shunichi Homma; Sujata Kori
Journal:  J Am Coll Cardiol       Date:  2006-08-28       Impact factor: 24.094

6.  Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes.

Authors:  Katarzyna Krzyzanowska; Friedrich Mittermayer; Walter Krugluger; Christoph Schnack; Martin Hofer; Michael Wolzt; Guntram Schernthaner
Journal:  Atherosclerosis       Date:  2006-01-18       Impact factor: 5.162

Review 7.  Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease.

Authors:  Alexander E Fraley; Sotirios Tsimikas
Journal:  Curr Opin Lipidol       Date:  2006-10       Impact factor: 4.776

8.  Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease.

Authors:  M Nylaende; A Kroese; E Stranden; B Morken; G Sandbaek; A K Lindahl; H Arnesen; I Seljeflot
Journal:  Vasc Med       Date:  2006-02       Impact factor: 3.239

Review 9.  Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudication.

Authors:  William R Hiatt; Mori J Krantz
Journal:  Vasc Med       Date:  2006-02       Impact factor: 3.239

10.  Ankle brachial index as a marker of atherosclerosis in Chinese patients with high cardiovascular risk.

Authors:  Buaijiaer Hasimu; Jue Li; Tomohiro Nakayama; Jinming Yu; Jingang Yang; Xiankai Li; Dayi Hu
Journal:  Hypertens Res       Date:  2006-01       Impact factor: 3.872

View more
  29 in total

Review 1.  Genetics of peripheral artery disease.

Authors:  Nicholas J Leeper; Iftikhar J Kullo; John P Cooke
Journal:  Circulation       Date:  2012-06-26       Impact factor: 29.690

2.  A compendium on peripheral arterial disease.

Authors:  John P Cooke; Zhen Chen
Journal:  Circ Res       Date:  2015-04-24       Impact factor: 17.367

Review 3.  Peripheral artery disease. Part 1: clinical evaluation and noninvasive diagnosis.

Authors:  Joe F Lau; Mitchell D Weinberg; Jeffrey W Olin
Journal:  Nat Rev Cardiol       Date:  2011-05-31       Impact factor: 32.419

4.  Spatial heterogeneity in skeletal muscle microvascular blood flow distribution is increased in the metabolic syndrome.

Authors:  Jefferson C Frisbee; Fan Wu; Adam G Goodwill; Joshua T Butcher; Daniel A Beard
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-07-20       Impact factor: 3.619

5.  Evaluation of 6- and 12-month supervised exercise training on strength and endurance parameters in patients with peripheral arterial disease.

Authors:  Magdalena Pilz; Elisabeth Kandioler-Honetz; Alfa Wenkstetten-Holub; Waltraud Doerrscheidt; Rudolf Mueller; Robert Wolfgang Kurz
Journal:  Wien Klin Wochenschr       Date:  2014-05-14       Impact factor: 1.704

6.  Peripheral artery disease, biomarkers, and darapladib.

Authors:  Jeffrey S Berger; Christie M Ballantyne; Michael H Davidson; Joel L Johnson; Elizabeth A Tarka; Denise Lawrence; Trupti Trivedi; Andrew Zalewski; Emile R Mohler
Journal:  Am Heart J       Date:  2011-05       Impact factor: 4.749

7.  Oxidation-specific biomarkers and risk of peripheral artery disease.

Authors:  Monica L Bertoia; Jennifer K Pai; Jun-Hee Lee; Adam Taleb; Michel M Joosten; Murray A Mittleman; Xiaohong Yang; Joseph L Witztum; Eric B Rimm; Sotirios Tsimikas; Kenneth J Mukamal
Journal:  J Am Coll Cardiol       Date:  2013-03-26       Impact factor: 24.094

8.  Prognostic value of cardiovascular MR imaging biomarkers on outcome in peripheral arterial disease: a 6-year follow-up pilot study.

Authors:  Harrie van den Bosch; Jos Westenberg; Wikke Setz-Pels; Erik Kersten; Alexander Tielbeek; Lucien Duijm; Johannes Post; Joep Teijink; Albert de Roos
Journal:  Int J Cardiovasc Imaging       Date:  2016-05-21       Impact factor: 2.357

9.  Associations of candidate biomarkers of vascular disease with the ankle-brachial index and peripheral arterial disease.

Authors:  Zi Ye; Zeenat Ali; George G Klee; Thomas H Mosley; Iftikhar J Kullo
Journal:  Am J Hypertens       Date:  2013-01-11       Impact factor: 2.689

Review 10.  Translational Bioinformatics Approaches to Drug Development.

Authors:  Ben Readhead; Joel Dudley
Journal:  Adv Wound Care (New Rochelle)       Date:  2013-11       Impact factor: 4.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.